checkAd
    Startseite > Aktien > Candel Therapeutics > Nachrichten
    Candel Therapeutics Aktie
    9,5900
     
    USD
    +8,36 %
    +0,7400 USD
    Letzter Kurs 02:00:00 Nasdaq
    9,5500
     
    USD
    300 STK
    Geldkurs 07.05.24
    9,5800
     
    USD
    100 STK
    Briefkurs 07.05.24
    ISIN: US1374041093 · WKN: A3CVW2 · SYM: CADL · USA

    Neueste Nachrichten

    Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
    25.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
    11.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
    09.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
    04.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
    28.03.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
    28.03.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
    05.03.24 · globenewswire · Candel Therapeutics
    CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
    13.02.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
    05.02.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN Discovery Platform, and Key Clinical Readouts for CAN-2409
    28.11.23 · globenewswire · Candel Therapeutics
    Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
    09.11.23 · globenewswire · Candel Therapeutics
    Candel Therapeutics Presents Preclinical Data from its enLIGHTEN Discovery Platform at SITC
    04.11.23 · globenewswire · Candel Therapeutics